Cure My Disease

Don't miss your cure!

 Log in / Sign up

Could ozempic help cystic fibrosis diabetes? tiny study hints at yes

NCT ID NCT05788965

Disease control Sponsor: University of Minnesota Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This pilot study tested the drug semaglutide (a GLP-1 receptor agonist, like Ozempic) in 8 overweight or obese adults with cystic fibrosis-related diabetes who were already using insulin. The goal was to see if adding semaglutide could safely help with weight loss and improve blood sugar control over 12 weeks. Because it was a small, open-label study with no comparison group, the results are very preliminary.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
semaglutide (a GLP-1 receptor agonist, also known as Ozempic/Wegovy)
What this could lead to
If it works, this could point toward a new add-on treatment to help manage weight and blood sugar in people with cystic fibrosis-related diabetes.
What could go wrong
This is a very small pilot study with only 8 participants, no placebo group, and short follow-up. Results may not apply to all patients, and side effects like nausea or gastrointestinal issues are possible.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 2/3

Runs two stages together: whether the treatment works, then large-scale confirmation.

Participants

8 people

The number who actually took part.

Started

Oct 2023

Finished

Dec 2024

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Adult subjects 18 years or older with CFRD and on insulin treatment * BMI \>26 kg/m2 * Diagnosis of pancreatic insufficiency (based on treatment with pancreatic enzyme replacement therapy) * A participant who is capable of becoming pregnant must agree to take precautions that are effective in preventing pregnancy throughout this study. These methods could include one of the following 1. Complete abstinence from sexual intercourse; 2. Oral, injectable, or implanted hormonal contraceptives 3. Intrauterine device 4. Tubal ligation Exclusion Criteria: * personal or family history of medullary thyroid cancer or multiple endocrine neoplasia syndrome type 2 (MEN2) * acute pulmonary exacerbation requiring IV antibiotics or systemic glucocorticoids within 4 weeks prior to baseline study procedures * gastrointestinal(GI) symptom exacerbation defined by current nausea/vomiting or diarrhea at the baseline assessment * history of chronic GI problems requiring hospitalization in the 1 year prior to baseline * history of clinically symptomatic pancreatitis * history of clinically significant gastroparesis * history of eating disorders * less than 24 weeks since start of a new CFTR corrector/modulator therapy * pregnancy or lactation * severe CF liver disease * chronic kidney disease * history of suicide attempts or active suicidal ideation * Non-English speakers and those unable to read in English

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Cystic fibrosis are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

cystic fibrosis cystic fibrosis-related diabetes

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Cystic fibrosis Cystic fibrosis-related diabetes

Contacts and locations

Locations

  • University of Minnesota

    Minneapolis, Minnesota, 55455, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.